Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC.
Ruiz L, Romeu J, Martínez-Picado J, Schmit JC, Vandamme AM, Balagué M, Cabrera C, Puig T, Tural C, Segura A, Sirera G, De Clercq E, Clotet B. Ruiz L, et al. Among authors: balague m. AIDS. 1996 Dec;10(14):F61-6. doi: 10.1097/00002030-199612000-00003. AIDS. 1996. PMID: 8970679 Clinical Trial.
High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response.
Paredes R, Puig T, Arnó A, Negredo E, Balagué M, Bonjoch A, Jou A, Tuldrà A, Tural C, Sirera G, Veny A, Romeu J, Ruiz L, Clotet B. Paredes R, et al. Among authors: balague m. J Acquir Immune Defic Syndr. 1999 Oct 1;22(2):132-8. doi: 10.1097/00126334-199910010-00004. J Acquir Immune Defic Syndr. 1999. PMID: 10843526 Clinical Trial.
Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients.
Ruiz L, Nijhuis M, Boucher C, Puig T, Bonjoch A, Martínez-Picado J, Marfil S, de Jong D, Burger D, Arnó A, Balagué M, Clotet B. Ruiz L, et al. Among authors: balague m. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Sep 1;19(1):19-28. doi: 10.1097/00042560-199809010-00003. J Acquir Immune Defic Syndr Hum Retrovirol. 1998. PMID: 9732064 Clinical Trial.
Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load.
Arnó A, Ruiz L, Juan M, Jou A, Balagué M, Zayat MK, Marfil S, Martínez-Picado J, Martínez MA, Romeu J, Pujol-Borrell R, Lane C, Clotet B. Arnó A, et al. Among authors: balague m. J Infect Dis. 1999 Jul;180(1):56-60. doi: 10.1086/314831. J Infect Dis. 1999. PMID: 10353861 Clinical Trial.
Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy.
Tuldrà A, Fumaz CR, Ferrer MJ, Bayés R, Arnó A, Balagué M, Bonjoch A, Jou A, Negredo E, Paredes R, Ruiz L, Romeu J, Sirera G, Tural C, Burger D, Clotet B. Tuldrà A, et al. Among authors: balague m. J Acquir Immune Defic Syndr. 2000 Nov 1;25(3):221-8. doi: 10.1097/00126334-200011010-00003. J Acquir Immune Defic Syndr. 2000. PMID: 11115952 Clinical Trial.
Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.
Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balagué M, Gel S, Bonjoch A, Fumaz CR, Johnston S, Romeu J, Lange J, Clotet B; Spanish Lipodystrophy Group. Ruiz L, et al. Among authors: balague m. J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):229-36. doi: 10.1097/00126334-200107010-00003. J Acquir Immune Defic Syndr. 2001. PMID: 11464141 Clinical Trial.
Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
Negredo E, Paredes R, Bonjoch A, Tuldrà A, Fumaz CR, Gel S, Garcés B, Johnston S, Arnó A, Balagué M, Jou A, Tural C, Sirera G, Romeu J, Cruz L, Francia E, Domingo P, Arrizabalaga J, Ruiz I, Arribas JR, Ruiz L, Clotet B. Negredo E, et al. Among authors: balague m. Antivir Ther. 1999;4 Suppl 3:23-8. Antivir Ther. 1999. PMID: 16021868 Clinical Trial.
Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression.
Negredo E, Cruz L, Paredes R, Ruiz L, Fumaz CR, Bonjoch A, Gel S, Tuldrà A, Balagué M, Johnston S, Arnó A, Jou A, Tural C, Sirera G, Romeu J, Clotet B. Negredo E, et al. Among authors: balague m. Clin Infect Dis. 2002 Feb 15;34(4):504-10. doi: 10.1086/324629. Epub 2002 Jan 2. Clin Infect Dis. 2002. PMID: 11797178 Clinical Trial.
22 results